Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year. Methods We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020). Results There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths. Conclusions During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT.
Abstract
Background and Purpose Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year. Methods We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020). Results There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths. Conclusions During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT.
참고문헌 (41)
- Ahmad FB, "The leading causes of death in the US for 2020", JAMA, 325, pp.1829~1830 (2021)
- Chou SH, "Global incidence of neurological manifestations among patients hospitalized with COVID-19 : a report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium", JAMA Netw Open, 4, pp.e2112131~ (2021)
- Spudich S, "Nervous system consequences of COVID-19", Science, 375, pp.267~269 (2022)
- Elkind MSV, "Infection as a stroke risk factor and determinant of outcome after stroke", Stroke, 51, pp.3156~3168 (2020)
- Yaghi S, "SARS-CoV-2 and stroke in a New York healthcare system", Stroke, 51, pp.2002~2011 (2020)
- Siegler JE, "Cerebrovascular events and outcomes in hospitalized patients with COVID-19 : the SVIN COVID-19 Multinational Registry", Int J Stroke, 16, pp.437~447 (2021)
- Esenwa C, "Biomarkers of coagulation and inflammation in COVID-19-associated ischemic stroke", Stroke, 52, pp.e706~e709 (2021)
- Ma A, "Stroke and thromboprophylaxis in the era of COVID-19", J Stroke Cerebrovasc Dis, 30, pp.105392~ (2021)
- Abdalkader M, "Cerebral venous sinus thrombosis in COVID-19 patients : a multicenter study and review of literature", J Stroke Cerebrovasc Dis, 30, pp.105733~ (2021)
- Rana A, "Stroke and neurointervention in the COVID-19 pandemic : a narrative review", Expert Rev Med Devices, 18, pp.523~531 (2021)
- Devasagayam S, "Cerebral venous sinus thrombosis incidence is higher than previously thought : a retrospective population-based study", Stroke, 47, pp.2180~2182 (2016)
- Otite FO, "Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States", Neurology, 95, pp.e2200~e2213 (2020)
- Coutinho JM, "The incidence of cerebral venous thrombosis : a cross-sectional study", Stroke, 43, pp.3375~3377 (2012)
- Yaghi S, "Direct oral anticoagulants versus warfarin in the treatment of cerebral venous thrombosis (ACTION-CVT): a multicenter international study", Stroke, 53, pp.728~738 (2022)
- Alimohammadi A, "Updates in cerebral venous thrombosis", Curr Cardiol Rep, 24, pp.43~50 (2022)
- Klein P, "Factors associated with adverse outcomes following CVT: analysis of ACTION-CVT", Eur Stroke J, 7(1 Suppl), pp.98~ (2022)
- Al-Mufti F, "Cerebral venous thrombosis in COVID-19 : a New York Metropolitan Cohort Study", AJNR Am J Neuroradiol, 42, pp.1196~1200 (2021)
- Sánchez van Kammen M, "Frequency of thrombocytopenia and platelet factor 4", heparin antibodies in patients with cerebral venous sinus thrombosis prior to the COVID-19 pandemic, 2021, pp.326, 332~338
- Siegler JE, "Cerebral vein thrombosis with vaccineinduced immune thrombotic thrombocytopenia", Stroke, 52, pp.3045~3053 (2021)
- Sánchez van Kammen M, "Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia", JAMA Neurol, 78, pp.1314~1323 (2021)
- Perry RJ, "Cerebral venous thrombosis after vaccination against COVID-19 in the UK : a multicentre cohort study", Lancet, 398, pp.1147~1156 (2021)
- Nogueira RG, "Global impact of COVID-19 on stroke care", Int J Stroke, 16, pp.573~584 (2021)
- Nogueira RG, "Global impact of COVID-19 on stroke care and IV thrombolysis", Neurology, 96, pp.e2824~e2838 (2021)
- Raymaekers V, "The impact of COVID-19 on acute stroke care in Belgium", Acta Neurol Belg, 121, pp.1251~1258 (2021)
- Sacco S, "Reduced admissions for cerebrovascular events during COVID-19 outbreak in Italy", Stroke, 51, pp.3746~3750 (2020)
- Seiffert M, "Temporal trends in the presentation of cardiovascular and cerebrovascular emergencies during the COVID-19 pandemic in Germany : an analysis of health insurance claims", Clin Res Cardiol, 109, pp.1540~1548 (2020)
- Nguyen TN, "Decline in subarachnoid haemorrhage volumes associated with the first wave of the COVID-19pandemic", Stroke Vasc Neurol, 6, pp.542~552 (2021)
- Ramos-Araque ME, "Stroke etiologies in patients with COVID-19 : the SVIN COVID-19 multinational registry", BMC Neurol, 21, pp.43~ (2021)
- "COVID-19 pandemic by country and territory: 5. Timeline of first confirmed cases by country or territory" (2022)[URL]
- "Vaccine-induced immune thrombotic thrombocytopenia" (2022)[URL]
- Nguyen TN, "Global impact of the COVID19 pandemic on subarachnoid hemorrhage hospitalizations, aneurysm treatment, and in-hospital mortality: 1 year follow-up", Eur Stroke J, 7(1 Suppl), pp.553~ (2022)
- James E. Siegler, "Therapeutic Trends of Cerebrovascular Disease during the COVID-19 Pandemic and Future Perspectives", 대한뇌졸중영문학회지, 24(2), pp.179~188 (2022), 대한뇌졸중학회[DOI]
- Long CV, "Brain venography performance following the pause of Ad.26.COV2.S COVID-19 vaccine administration", J Thromb Thrombolysis, 53, pp.359~362 (2022)
- Baldini T, "Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection : a systematic review and meta-analysis", Eur J Neurol, 28, pp.3478~3490 (2021)
- Cavalcanti DD, "Cerebral venous thrombosis associated with COVID-19", AJNR Am J Neuroradiol, 41, pp.1370~1376 (2020)
- Nwajei F, "Cerebral venous sinus thromboses in patients with SARS-CoV-2 infection : three cases and a review of the literature", J Stroke Cerebrovasc Dis, 29, pp.105412~ (2020)
- Taquet M, "Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases", EClinicalMedicine, 39, pp.101061~ (2021)
- Nannoni S, "Stroke in COVID-19 : a systematic review and meta-analysis", Int J Stroke, 16, pp.137~149 (2021)
- Dmytriw AA, "Acute ischaemic stroke associated with SARSCoV-2 infection in North America", J Neurol Neurosurg Psychiatry, 93, pp.360~368 (2022)
- Tamer Roushdy, "Stroke services in Africa: What is there and what is needed", International Journal of Stroke, 17(9), pp.972~982 (2022), SAGE Publications[DOI]
- Nguyen TN, "Noncontrast computed tomography vs computed tomography perfusion or magnetic resonance imaging selection in late presentation of stroke with large-vessel occlusion", JAMA Neurol, 79, pp.22~31 (2022)